What question did this study set out to answer?

To investigate response to combined checkpoint and BTK inhibition in patients with Richter transformation and identify biomarkers for survival.

December 8, 2025Blood

Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial

View Full Paper

Ask AI

Bookmark

Authors

RWRebecca Wurm‐KuczeraHumboldt-Universität zu Berlin CAChidimma Agatha AkpaPharis Biotec (Germany)ETEugen TauschUniversity Hospital Ulm

Discussion

Member takes

Implication

Phase II trial found combined therapy improves progression-free survival in CLL with Richter transformation, suggesting potential biomarkers for response.

Key Points

To investigate response to combined checkpoint and BTK inhibition in patients with Richter transformation and identify biomarkers for survival.
Phase II RT1 trial with patients having Richter transformation
Received tislelizumab and zanubrutinib treatment
Evaluated overall response rate, progression-free survival, and other endpoints via clinical and translational analyses
Conducted RNA sequencing and whole-genome sequencing for biomarker correlation
Overall response rate achieved 58.3% with a median duration of response of 17.1 months
Median progression-free survival was 10.0 months
Identified key biomarkers associated with response, including gene expression and somatic mutations

Cite This Study

Wurm‐Kuczera et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d000 https://doi.org/10.1182/blood-2025-90

View Full Paper

Ask AI

Bookmark

Implication

Phase II trial found combined therapy improves progression-free survival in CLL with Richter transformation, suggesting potential biomarkers for response.

Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider